Senti Biosciences Inc. Common Stock (SNTI)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable businesses that earn consistent profits and produce cash. Senti Biosciences is a clinical-stage biotechnology company, not that. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported revenue of $17,000 and a net loss of $12.8 million, or diluted EPS of -$0.41. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $16,000 and net loss was $4.2 million, or diluted EPS -$0.14. For FY2025, ended 2025-12-31, revenue was $22,000 and net loss was $61.4 million, or diluted EPS -$2.73. FY2024, ended 2024-12-31, had no revenue reported and a net loss of $52.8 million, or diluted EPS -$12.03. FY2023, ended 2023-12-31, had revenue of $2.0 million and a net loss of $71.1 million, or diluted EPS -$16.01. The revenue base has effectively vanished while losses remain enormous. FairStock calculations show trailing free cash flow of -$38.1 million against a $7.9 million market cap, a -479.1% FCF yield, P/B of 5.61, ROE of -466.46%, ROCE of -65.57%, D/E of 5.17, Altman Z-score of -17.29, and Piotroski F-score of 2/9. The $0.25 close on 2026-10-13 leaves the shares near their 52-week low. The science of off-the-shelf CAR-NK cells with gene circuits may have long-term promise, but there is no proven competitive moat, no earnings, and a weak balance sheet. FairStock score 16/100 and no Lynch category, because losses occurred in each of the last four years. This is speculation, not value investing.

In plain English: Senti Biosciences is a small experimental-stage company developing cell therapies made from donor cells to fight cancer. It has almost no revenue and loses many millions of dollars, so the business looks very weak. At 25 cents a share, the price is low, but the company is not making money and is using lots of cash, so it does not look cheap on its numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer